Figure 2.
3D MRI tumor growth calculations. A. Representative post-gadolinium enhancement T1 sequence axial sections through the tumor mass are shown, corresponding to the initiation of alkylating chemotherapy inclusive of TMZ and immediately prior to cessation of this treatment. The MSH6-positive case on the left shows recurrent tumor sample xT3692; 254 days elapsed between initial and final scan. The MSH6-negative case on the right shows recurrent glioblastoma samples xT4161; 249 days elapsed between initial and final scan. Multiple axial imaging sections through the tumor mass were summated to determine enhancing tumor volume. B. For 11 MSH6-positive tumors, volume change versus time elapsed between initial and followup MRI scan. The median rate of volume change was 0.001 cc/d. C. For 9 MSH6-negative tumors, volume change versus time, with a median rate of 0.106 cc/d. Full clinical/radiologic dataset available as Supplementary Table 1.